Alzheon

Alzheon
Private
Industry Pharmaceutical
Founded 2013
Headquarters Framingham, Massachusetts, United States
Key people
 Martin Tolar, MD, PhD (CEO)
Jean-Pierre Garnier (Chairman of the Board of Directors)
Website www.alzheon.com

Alzheon is a U.S. clinical-stage biopharmaceutical company based in Framingham, Massachusetts.[1] The company is developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders.[2]

History

Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, who serves as president and CEO of the organization.[3] Alzheon completed a $10 million Series A round of financing in April 2015[4][5] and started the Phase lb bridging clinical program for ALZ-801, which was completed in July 2016.[6][7]

In December 2015, Alzheon appoints Jean-Pierre Garnier, PhD, as Chairman of the Board of Directors.[8]

In January 2017, Alzheon appoints Stanley B. Prusiner, MD, As Chair Of Scientific Advisory Board.[9]

Pipeline

The company's lead clinical candidate is ALZ-801 an oral small molecule inhibitor of amyloid aggregation and neurotoxicity and an optimized, oral prodrug of the active molecule tramiprosate.[10] Originally developed by a Canadian firm formerly called Neurochem,[11] the drug is expected to target amyloid plaques.[12]

References

  1. ↑ Young, Susan (Mar 10, 2016). "Startup Finds Hope in Second Look at "Failed" Alzheimer's Drugs". MIT Technology Review. Retrieved August 24, 2016.
  2. ↑ Lash, Alex (11 March 2016). "Failed Alzheimer's Drug To Get Another Shot, If Investors Pony Up". Xconomy. Retrieved 29 April 2017.
  3. ↑ Seiffert, Don (March 20, 2015). "Lexington's Alzheon gives its own Alzheimer's news to rival Biogen's". Retrieved August 23, 2016 – via Boston Business Journal.
  4. ↑ Fidler, Ben (8 April 2015). "Alzheon Gets $10M to Take Castoff Alzheimer's Drug Into Pivotal Test". Xconomy. Retrieved 29 April 2017.
  5. ↑ Billings, Mike (April 8, 2015). "In a Hot Market, Freestyle Capital Raises Larger Fund". The Wall Street Journal. Retrieved August 25, 2016.
  6. ↑ "'Gene-dose' effect for Alzheon's ALZ-801, a drug targeting Alzheimer's". The Pharma Letter. Retrieved 29 April 2017.
  7. ↑ Fernandes, PhD, Joana (31 March 2017). "Early Alzheimer's Patients with Risk Gene Respond to ALZ-801 in Studies". Alzheimer's News Today. Retrieved 29 April 2017.
  8. ↑ Petroni, Susan (16 December 2015). "Alzheon Appoints Former GlaxoSmithKline CEO Jean-Pierre Garnier as Board Chair". Patch Media. Retrieved 17 July 2017.
  9. ↑ Begley, Sharon (4 January 2017). "Biotech with big Alzheimer's dreams recruits prion pioneer". Stat News. Retrieved 29 April 2017.
  10. ↑ "Alzheon's tramiprosate shows meaningful effects in Alzheimer's trial". March 12, 2016. Retrieved August 24, 2016 – via The Pharma Letter.
  11. ↑ LaMattina, John. "A Little-Known Drug Company Could Have The Answer For Some Alzheimer's Patients". Forbes. Retrieved 29 April 2017.
  12. ↑ Weisman, Robert (July 26, 2016). "Framingham startup plans trials of Alzheimer's treatment". Retrieved August 24, 2015 – via Boston Globe.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.